The clinical association of programmed cell death protein 4 (PDCD4) with solid tumors and its prognostic significance: a meta-analysis

Li, John Zeng Hong; Gao, Wei; Ho, Wai-Kuen; Lei, Wen Bin; Wei, William Ignace; Chan, Jimmy Yu-Wai; Wong, Thian-Sze

doi:10.1186/s40880-016-0158-3

Table 3 Subgroup analysis on the associations between PDCD4 expression and OS, DSS, and DFS/RFS of patients with solid tumors

From: The clinical association of programmed cell death protein 4 (PDCD4) with solid tumors and its prognostic significance: a meta-analysis

Parameter	OS					DSS					DFS/RFS
Parameter	Reference(s)	HR	95% CI	I ² (%)	P	References	HR	95% CI	I ² (%)	P	References	HR	95% CI	I ² (%)	P
Total	[7, 15, 17, 18, 24, 28–31, 33]	2.24	1.93–2.60	42.1	0.025	[24, 28, 32, 34]	3.59	1.23–10.50	80.5	0.002	[29–31, 33, 35]	2.01	1.58–2.56	28.6	0.181
Univariate	[15, 18, 29–31]	2.05	1.69–2.49	59.4	0.016	None	NA	NA	NA	NA	[29–31]	2.05	1.16–3.63	51.1	0.105
Multivariate	[7, 17, 18, 24, 28–31, 33]	2.52	2.01–3.16	19.6	0.251	[24, 28, 32, 34]	3.59	1.23–10.50	80.5	0.002	[29–31, 33, 35]	2.37	1.69–3.33	0	0.456
Brain tumor	None	NA	NA	NA	NA	[32]	15.87	3.62–71.43	NA	NA	None	NA	NA	NA	NA
Univariate	None	NA	NA	NA	NA	None	NA	NA	NA	NA	None	NA	NA	NA	NA
Multivariate	None	NA	NA	NA	NA	[32]	15.87	3.62–71.43	NA	NA	None	NA	NA	NA	NA
Head and neck cancer	[18, 24, 29]	3.44	2.38–4.98	41.9	0.142	[24]	5.05	1.12–62.50	NA	NA	[29]	2.10	1.30–3.39	47.4	0.149
Univariate	[18, 29]	10.70	0.58–197.75	74.5	0.047	None	NA	NA	NA	NA	[29]	7.46	1.04–52.63	NA	NA
Multivariate	[18, 24, 29]	3.24	1.93–5.45	29.7	0.241	[24]	5.05	1.12–62.50	NA	NA	[29]	1.94	1.19–3.18	52.4	0.147
Breast cancer	[30]	1.86	1.36–2.54	28.1	0.238	None	NA	NA	NA	NA	[30]	1.23	0.79–1.92	NA	NA
Univariate	[30]	1.61	1.09–2.38	NA	NA	None	NA	NA	NA	NA	[30]	1.23	0.79–1.92	NA	NA
Multivariate	[30]	2.38	1.43–4.00	NA	NA	None	NA	NA	NA	NA	None	NA	NA	NA	NA
Digestive system cancer	[7, 15, 28, 31]	2.12	1.75–2.56	36.2	0.101	[28]	1.31	1.00–1.72	NA	NA	[31, 33]	2.57	1.74–3.78	0	0.877
Univariate	[15, 31]	2.14	1.49–3.06	43.8	0.130	None	NA	NA	NA	NA	[31]	2.50	1.45–4.30	0	0.857
Multivariate	[7, 15, 28, 31]	2.33	1.73–3.13	36.6	0.149	[28]	1.31	1.00–1.72	NA	NA	[31, 33]	2.64	1.52–4.58	0	0.562
Gynecologic tumor	None	NA	NA	NA	NA	[34]	3.36	1.43–7.81	NA	NA	[35]	3.42	1.41–8.33	NA	NA
Univariate	None	NA	NA	NA	NA	None	NA	NA	NA	NA	None	NA	NA	NA	NA
Multivariate	None	NA	NA	NA	NA	[34]	3.36	1.43–7.81	NA	NA	[35]	3.42	1.41–8.33	NA	NA
Urinary system cancer	[17]	3.16	1.06–9.41	NA	NA	None	NA	NA	NA	NA	None	NA	NA	NA	NA
Univariate	None	NA	NA	NA	NA	None	NA	NA	NA	NA	None	NA	NA	NA	NA
Multivariate	[17]	3.16	1.06–9.41	NA	NA	None	NA	NA	NA	NA	None	NA	NA	NA	NA
Asian	[7, 15, 17, 18, 24, 28, 31]	2.46	2.06–2.95	23.5	0.193	[24, 32, 34]	5.67	2.13–5.12	36.6	0.206	[31, 33, 35]	2.69	1.88–3.83	0	0.908
Univariate	[15, 18, 31]	2.34	1.66-3.30	50.6	0.072	None	NA	NA	NA	NA	[31]	2.50	1.45–4.30	0	0.857
Multivariate	[7, 17, 24, 28, 31]	3.05	2.26–4.11	0.0	0.750	[24, 32, 34]	5.67	2.13–5.12	36.6	0.206	[31, 33, 35]	2.84	1.78–4.53	0	0.708
European	[28]	1.56	1.05–2.67	NA	NA	[28]	1.31	1.00–1.72	NA	NA	None	NA	NA	NA	NA
Univariate	None	NA	NA	NA	NA	None	NA	NA	NA	NA	None	NA	NA	NA	NA
Multivariate	[28]	1.56	1.05–2.67	NA	NA	[28]	1.31	1.00–1.72	NA	NA	None	NA	NA	NA	NA
North American	[29, 30]	1.99	1.46–2.71	71.7	0.014	None	NA	NA	NA	NA	[29, 30]	1.58	1.14–2.18	52.9	0.095
Univariate	[29, 30]	7.95	0.20–311.36	83.6	0.014	None	NA	NA	NA	NA	[29, 30]	2.33	0.43–12.57	67.5	0.080
Multivariate	[29]	2.56	1.54–4.25	66.9	0.082	None	NA	NA	NA	NA	[29]	1.94	1.19–3.18	52.4	0.147
Publication bias
Begg’s test					0.940					0.308					0.902
Egger’s test					0.744					0.215					0.550

OS overall survival, DSS disease-specific survival, DFS disease-free survival, RFS relapse-free survival, HR hazard ratio, CI confidence interval, NA not available

Back to article page

ISSN: 2523-3548

Contact us

General enquiries: info@biomedcentral.com

Cancer Communications

Contact us